









4/2/07

RELATED CASE STATEMENT

SERIAL NO. 10/531,533	FILING DATE April 25, 2006	ATTY. DOCKET NO. 13566.105012
APPLICANT Glynn Thomas Faircloth et al.		GROUP ART UNIT / EXAMINER 1654 / Maury Audet

PENDING U.S. PATENT APPLICATIONS

EXAM. INITIAL	PATENT APPLICATION SERIAL NUMBER	FILING DATE	NAME OF FIRST-NAMED APPLICANT		
	10/182,881	06-3-2003	Fernando Albericio et al.		
	10/546,758	08-24-2005	Miguel Angel Izquierdo Delso		
	10/492,670	11-03-2004	Jose Jimeno		
	10/399,571	11-14-2003	Glynn Faircloth		
	10/642,006	08-14-2003	Paul Scheuer		
	10/570,734	03-06-2006	Fernando Albericio Palomera		
	11/587,177	10-19-2006	Andres Francesch Solloso		

EXAMINER 	DATE CONSIDERED 09/07
--	---------------------------------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


FORM PTO 1519a

INFORMATION DISCLOSURE STATEMENT




Applicant (s):	Glynn Thomas Faircloth et al.	Serial No.:	10/531,533
Filing Date:	April 25, 2006	Group Art Unit:	1654
Examiner:	Maury Audet	Confirmation:	1346

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Issue Date	Name	Class	Subclass	Filing Date
	US 6,011,010	Jan. 4, 2000	Gravalos et al.			
	US 5,849,704	Dec. 15, 1998	Sorensen et al.			
	US 4,959,175	Sep. 25, 1990	Yatzidis			
	US 5,932,189	Aug. 3, 1999	Dean et al.			
	US 2004/0052764	Mar. 18, 2004	Hildinger et al.			
	US 2003/0157685	Aug. 21, 2003	Zervos			
	US 2004/0214755	Oct. 28, 2004	Albericio et al.			
	US 2004/0067895	Apr. 8, 2004	Faircloth et al.			

Examiner 	Date Considered 09/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



FORM PTO 1449b			
INFORMATION DISCLOSURE STATEMENT			
Applicant (s):	Glynn Thomas Faircloth et al.	Serial No.:	10/531,533
Filing Date:	April 25, 2006	Group Art Unit:	1654
Examiner:	Maury Audet	Confirmation:	1346

FOREIGN PATENT DOCUMENTS						
Examiner Initial		Patent Number	Pub. Date	Country	Translation	
					YES	NO
	B1	WO 2004/075910	Sep. 10, 2004	WIPO		
	B2	WO 2005/023846	Mar. 17, 2005	WIPO		
	B3	WO 2005/103072	Nov. 3, 2005	WIPO		
	B4	WO 2001/58934	Aug. 16, 2001	WIPO		
	B5	WO 2002/36145	May 10, 2002	WIPO		
	B6	EP 0 838 221	Apr. 29, 1998	Europe		
	B7	WO 99/42125	Aug. 26, 1999	WIPO		
	B8	EP 0 610 078	Aug. 10, 1994	Europe		
Examiner 				Date Considered 09/07		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						


FORM PTO 1449b INFORMATION DISCLOSURE STATEMENT

Applicant (s):	Glynn Thomas Faircloth et al.	Serial No.:	10/531,533
Filing Date:	April 25, 2006	Group Art Unit:	1654
Examiner:	Maury Audet	Confirmation:	1346

OTHER REFERENCES (Citation, Author, Title, Date, Patent, Pages, Etc.)

	A1	G. M. Loudon, Organic Chemistry, Second Edition, Benjamin/Cummings Publishing Company, Inc., 1988, pages 924-926.
	A2	Nuijen B et al., "Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F" Drug Development and Industrial Pharmacy, vol. 27, No. 8, pages 767-780, 2001.
	A3	Faircloth G et al., "Preclinical development of kahalalide F, a new marine compound selected for clinical studies," Proceedings of the American Association for Cancer Research Annual, no. 41, March 2000 (2000-03), pages 600-601, XP001097542, 91 st Annual Meeting of the American Association for Cancer Research, San Francisco CA, USA; April 01-05, 2000, March, 2000 ISSN: 0197-016X
	A4	Luber-Narod J et al., "Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity." Toxicology In Vitro, vol. 15, no. 4-5, August 2001 (2001-08), pages 571-577, XP002225749, ISSN: 0887-2333, page 576, column 2, paragraph 2
	A5	Brown Alan P et al., "Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat." Cancer Chemotherapy and Pharmacology. Germany Oct 2002, vol. 50, no. 4, October 2002 (2002-10), pages 333-340, XP002225750 ISSN: 0344-5704 abstract
	A6	El Sayed, Khalid A. et al., "The Marine Environment: A Resource for Prototype Antimalarial Agents," Journal of Natural Toxins, Vol. 5, No. 2, pp. 261-285, 1996
	A7	Garcia-Rocha, Mar et al., "The antitumoral compound Kahalalide F acts on cell lysosomes," Cancer Letters, vol. 99, no. 1, pp. 43-50, 1996
	A8	Goetz, Gilles et al., "The Absolute Stereochemistry of Kahalalide F," Tetrahedron, vol. 55, pp. 7739-7746, 1999
	A9	Goetz, Gilles et al., "Two Acyclic Kahalalides from the Sacoglossan Mollusk Elysia rufescens," Journal of Natural Products, vol. 60, no. 6, p. 562-567, 1997
	A10	Hamann, Mark T. et al., "Kahalalide F: A Bioactive Depsipeptide from the Sacoglossan Mollusk Elysia rufescens and the Green Alga Bryopsis sp.," Journal of the American Chemical Society, vol. 115, no. 13, pp. 5825-5826, 1993

Examiner





09/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449b INFORMATION DISCLOSURE STATEMENT

Applicant (s):	Glynn Thomas Faircloth et al.	Serial No.:	10/531,533
Filing Date:	April 25, 2006	Group Art Unit:	1654
Examiner:	Maury Audet	Confirmation:	1346

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A11	Hamann, Mark T. et al., "Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia refuscens and Its Algal Diet Bryopsis sp.," The Journal of Organic Chemistry, vol. 61, no. 19, pp. 6594-6600, 1996
	A12	Hamann, Mark T. et al., "Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia refuscens and Its Algal Diet Bryopsis sp.," The Journal of Organic Chemistry, vol. 63, no. 14, pp. 4856, 1998
	A13	Horgen, F. David et al., "A New Depsipeptide from the Sacoglossan Mollusk Elysia ornate and the Green Alga Bryopsis Species," Journal of Natural Products, vol. 63, no. 1, pp. 152-154, 2000
	A14	Kan, Yukiko et al., "Kahalalide K: A New Cyclic Depsipeptide from the Hawaiian Green Alga Bryopsis Species," Journal of Natural Products, vol. 62, no. 8, pp. 1169-1172, 1999
	A15	Lopez-Macia, Angel et al., "Kahalalide B. Synthesis of a natural cyclodepsipeptide," Tetrahedron Letters, vol. 41, pp. 9765-9769, 2000
	A16	Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw Hill, New York (1996), Section X, Chemotherapy of Neoplastic Diseases, pages 1225-1229.
	A17	Hamann, Mark Todd, Ph.D., University of Hawaii (1992), "Biologically Active Constituents of Some Marine Invertebrates," UMI Dissertation Services, published October 1993.
	A18	Merck Manual, 11 th ed., pp. 456-459, 761-763, and 1368-1371; published 1969.
	A19	Lee Y S et al., "A convergent liquid-phase synthesis of salmon calcitonin" Journal of Peptide Research, Munksgaard International Publishers, Copenhagen DK, vol. 54, no. 5, October 1999 (1999-10), pages 328-335, XP000849313 ISSN: 1397-002X, figure 1
	A20	Bonnard Isabelle et al., "Stereochemistry of kahalalide F," Journal of Natural Products. Nov 2003, vol. 66, no. 11, November 2003 (2003-11), pages 1466-1470, XP002337530 ISSN: 0163-3864 abstract
	A21	Lopez-Macia et al., "Synthesis and Structure Determination of Kahalalide F." J. Am. Chem. Soc., vol. 123, no. 46, pages 11398-11401, published on web Oct. 27, 2001.

Examiner

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.